论文部分内容阅读
以外科手术切除的肝癌标本制备的细胞悬液和新建株的肝癌细胞为免疫原。籍多重免疫途经致敢ＢＡＬＢ／ｃ小鼠，经２０次融合，从近１０，０００个融合孔中，筛选出两株（ＨＡｂ２５，ＨＡｂ２７）肝癌单克隆抗体，在９４例肝癌、１４１例其他肝病组织，２６种正常组织，１２９例各组织系统的肝外恶性肿瘤组织上做了交叉反应。除ＨＡｂ２７与毛细胆管有弱的反应外，两株抗体与肝癌组织结合的阳性率高（８３．１５％，８５．１１％），仅与少数消化道肿瘤有交叉．１３１Ⅰ标记抗体进行放射免疫显像，最佳显像时间为７２ｈ，瘤／肝、瘤／血比值分别为５．０７～６．８４、１．２６～２．１３，可望为肝癌导向药物研究，提供新的载体。
Cell suspensions prepared from surgically resected HCC specimens and newly constructed HCC cells were used as immunogens. BALB / c mice were screened for multiple immunization by two rounds of confluence. Two monoclonal antibodies (HAb25, HAb27) were screened from nearly 10,000 confluent wells in 94 cases of HCC and 141 cases of other liver diseases Tissue, 26 kinds of normal tissue, 129 cases of each tissue system of extrahepatic malignant tumor tissue cross-reaction. Except HAb27 and capillary bile duct weak reaction, the positive rate of two antibodies binding with HCC (83.15%, 85.11%) was only cross with a few gastrointestinal tumors. 131 Ⅰ labeled antibody for radioimmunoimaging, the best imaging time was 72h, tumor / liver, tumor / blood ratio were 5.07 ~ 6.84,1.26 ~ 2.13, expected to be liver cancer-oriented drug research , Provide a new carrier.